Clinical trials: Thalidomide, completed
Multiple Myeloma
UARK 2003-33, Total Therapy III
There have been two previous Total Therapy studies for multiple myeloma (MM) at the Myeloma Institute for Research and Therapy (MIRT): Total Therapy I (from 1989 through 1994) and Total Therapy II (from 1996 to 2004).
- Trial name
- NCT00081939
- Testing
- Velcade, Thalidomide
- Where
- United States
- Volunteers
- 303 people
- Sponsor
- University of Arkansas
Obscure Gastrointestinal Bleeding, Angiodysplasia
Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation
Background: Repeated episodes of bleeding from gastrointestinal vascular malformations refractory to endoscopic or surgical therapy often pose a major therapeutic challenge.
- Conditions
- Obscure Gastrointestinal Bleeding, Angiodysplasia, Gastric Antral Vascular Ectasia, Thalidomide
- Trial name
- NCT00964496
- Testing
- Thalidomide, Iron
- Volunteers
- 55 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Unspecified Adult Solid Tumor, Protocol Specific
Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors
Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy such as irinotecan use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00062127
- Testing
- irinotecan hydrochloride, thalidomide, pharmacological study
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Non Neoplastic Condition, Precancerous Condition
Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
RATIONALE: Thalidomide may stop the growth of systemic mastocytosis by blocking blood flow to the disease. PURPOSE: This phase II trial is studying how well thalidomide works in treating patients with relapsed or progressive…
- Trial name
- NCT00769587
- Testing
- thalidomide
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Multiple Myeloma
Thalidomide to Patients With Previously Untreated Multiple Myeloma
The purpose of this study is to test the effect of thalidomide in patients with multiple myeloma. The patients receive either thalidomide or a placebo tablet (neither patient nor doctor know which of these are given) in addition…
- Trial name
- NCT00218855
- Testing
- thalidomide
- Where
- Norway
- Volunteers
- 363 people
- Sponsor
- Norwegian University of Science and Technology
Brain and Central Nervous System Tumors
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00006358
- Testing
- temozolomide, thalidomide
- Where
- 11 sites in United States
- Volunteers
- 44 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in…
- Trial name
- UPFRONT (NCT00507416)
- Testing
- Bortezomib, Dexamethasone, Melphalan
- Where
- 235 sites in United States, Puerto Rico
- Volunteers
- 502 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life
Four monthly treatments with pegylated liposomal doxorubicin, thalidomide and dexamethasone for newly diagnosed myeloma patients as induction therapy prior to high dose chemotherapy and autologous stem cell transplant.
- Trial name
- NCT00222105
- Testing
- Doxil, Thalidomide, Dexamethasone
- Volunteers
- 25 people
- Sponsor
- University of Kansas Medical Center
Mucositis Oral
Glutamine Combined With Thalidomide in Preventing Radiation-induced Oral Mucositis
The goal of this study is to compare glutamine combined with thalidomide with glutamine in preventing radiation-induced oral mucositis.
- Trial name
- NCT06031012
- Testing
- glutamine combined with thalidomide, glutamine alone
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Air Force Military Medical University, China
Tumors Metastatic to Brain
Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases
Randomized phase III trial to compare the effectiveness of radiation therapy with or without thalidomide in treating patients who have brain metastases. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00033254
- Testing
- radiation therapy, thalidomide, quality-of-life assessment
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphatic Leukemia
Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment
Despite certain notable progress, treatment of patients with Chronic Lymphatic Leukemia (CLL) is still disappointing. Although thanks to the use of treatment of (immune) chemotherapy, mainly based on fludarabine, rituximab and…
- Trial name
- LENDEX-LLC-09 (NCT01246557)
- Testing
- Lenalidomide, Dexamethasone
- Where
- 6 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Brain and Nervous System, Cancer
A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors
The study will try to answer these questions: 1. What is the highest dose of thalidomide brain cancer patients can receive safely in combination with irinotecan? 2.
- Trial name
- NCT00251797
- Testing
- Irinotecan, Thalidomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of New Mexico
Lung Cancer
Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as carboplatin and etoposide use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00061919
- Testing
- Carboplatin, etoposide & thalidomide
- Where
- United Kingdom
- Volunteers
- 724 people
- Sponsor
- University College, London
Brain and Central Nervous System Tumors
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
RATIONALE: Thalidomide may stop the growth of malignant glioma by stopping blood flow to the tumor. Drugs used in chemotherapy, such as procarbazine, work in different ways to stop tumor cells from dividing so they stop growing…
- Trial name
- NCT00079092
- Testing
- procarbazine hydrochloride, thalidomide
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Central Nervous System Tumor, Pediatric, Leukemia
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00357500
- Testing
- celecoxib, cyclophosphamide, etoposide
- Where
- 10 sites in United States
- Volunteers
- 101 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma and Plasma Cell Neoplasm
Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00008242
- Testing
- dexamethasone, doxorubicin hydrochloride, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma
Objective of this study is to characterize the steady-state pharmacokinetics (PK) of thalidomide when given orally as monotherapy to subjects with multiple myeloma.
- Trial name
- NCT01937442
- Testing
- Thalidomide Celgene™
- Where
- 7 sites in France, United Kingdom
- Volunteers
- 7 people
- Sponsor
- Celgene
Thalassemia
Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia
Thalidomide is known to have hypnosedative, immuno-modulatory and anti-angiogenic effects. The drug is widely used in several neoplastic disorders (e.g. multiple myeloma and malignant melanoma), inflammatory conditions (e.g.
- Trial name
- Thal-Thalido (NCT03651102)
- Testing
- Thalidomide and Hydroxyurea
- Where
- Pakistan
- Volunteers
- 654 people
- Sponsor
- Blood Diseases Clinic
Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma
Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165
The study seeks to provide long-term follow-up and/or to offer continued maintenance thalidomide (THALOMID) therapy to those patients enrolled in 20030165. Patients will be followed until withdrawal of consent, or death.
- Trial name
- NCT02507336
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Miami
Hormone-refractory Prostate Cancer
An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
Trial objectives: The primary objective is to determine the proportion of patients who have 50% decrease in PSA maintained for at least 4 weeks, in advanced hormone-refractory prostate cancer (HRPC) patients who receive…
- Trial name
- NCT00201357
- Testing
- Thalidomide (THADO)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Health Research Institutes, Taiwan